Ngenla Side Effects

Generic name: somatrogon

Medically reviewed by Drugs.com. Last updated on Aug 10, 2024.

Note: This document provides detailed information about Ngenla.

Applies to somatrogon: subcutaneous solution Side Effects associated with somatrogon. Some dosage forms listed on this page may not apply specifically to the brand name Ngenla.

Applies to somatrogon: subcutaneous solution.

Precautions

If you will be taking this medicine for a long time, it is very important that your doctor check you and your child's progress at regular visits. Blood and urine tests may be needed to check for any problems or unwanted effects that may be caused by this medicine.

This medicine may cause serious allergic reactions, including anaphylaxis and angioedema, which are life-threatening and require immediate medical attention. Tell your doctor right away if you or your child have a rash, itching, swelling of the face, tongue, or throat, trouble breathing, or chest pain after receiving this medicine.

Never share pens with others under any circumstances. It is not safe for one pen to be used for more than one person. Sharing needles or pens can result in transmission of hepatitis viruses, HIV, or other bloodborne illnesses.

Using this medicine may increase your or your child's risk of getting cancer. Talk to your doctor if you have concerns about this risk.

This medicine may affect blood sugar levels. Check with your doctor if you notice a change in the results of your or your child's blood or urine sugar tests or if you have any questions.

This medicine may cause an increased pressure in the head. Check with your doctor immediately if headache, nausea, vomiting, blurred vision, or any other change in vision occurs during treatment. Your doctor may want you to have your or your child's eyes checked by an ophthalmologist (eye doctor).

Check with your doctor right away if you or your child have decrease in amount of urine, noisy, rattling breathing, swelling of the fingers, hands, feet, or lower legs, or weight gain. These may be symptoms of fluid retention (extra water in the body).

Check with your doctor right away if you have darkening of skin, diarrhea, dizziness, fainting, loss of appetite, mental depression, nausea, skin rash, unusual tiredness or weakness, or vomiting. These may be symptoms of an adrenal gland problem (hypoadrenalism).

Pancreatitis (inflammation of the pancreas) has occurred rarely in some patients receiving somatrogon-ghla. Tell your doctor right away if you or your child have sudden and severe stomach pain, chills, constipation, nausea, vomiting, fever, or lightheadedness.

Check with your doctor right away if your child has hip and knee pain or limp. These may be symptoms of slipped capital femoral epiphysis (hip bone dislocation).

Do not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal or vitamin supplements.

Serious side effects of Ngenla

Along with its needed effects, somatrogon (the active ingredient contained in Ngenla) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking somatrogon:

Other side effects of Ngenla

Some side effects of somatrogon may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

For healthcare professionals

Applies to somatrogon: subcutaneous solution.

General adverse events

Adverse reactions occurring in 5% of patients or greater included injection site reactions, nasopharyngitis, headache, pyrexia, anemia, cough, vomiting, hypothyroidism, abdominal pain, rash, and oropharyngeal pain.^[Ref]

Dermatologic

• Common (1% to 10%): Rash generalized
• Frequency not reported: Lipoatrophy

Endocrine

• Common (1% to 10%): Hypothyroidism
• Uncommon (0.1% to 1%): Adrenal insufficiency

Gastrointestinal

• Very common (10% or more): Common (1% to 10%): Vomiting, abdominal pain, tonsillitis
• Frequency not reported (somatropin): Pancreatitis

Hematologic

• Very common (10% or more): Elevated eosinophils, increasing from normal at baseline over 12 months (29%)
• Common (1% to 10%): Anemia

Hypersensitivity

• Frequency not reported (somatropin): Severe systemic hypersensitivity reactions, including anaphylaxis and angioedema

Immunologic

• Very common (10% or more): Anti-drug antibodies (77.1%)

Local

• Very common (10% or more): Injection site reactions (up to 42.2%), including injection site pain (39%), injection site swelling/induration/hypertrophy/inflammation (10%)
• Common (1% to 10%): Injection site erythema, injection site pruritus, injection site hemorrhage

Metabolic

• Common (1% to 10%): Increased blood creatinine phosphokinase
• Frequency not reported: New onset type 2 diabetes mellitus, worsened glycemic control, fluid retention

Musculoskeletal

• Common (1% to 10%): Arthralgia, pain in extremity
• Frequency not reported: Slipped capital femoral epiphysis, progression of scoliosis, myositis

Nervous system

• Very common (10% or more): Headache (up to 16.5%)
• Frequency not reported (somatropin): Intracranial hypertension (with papilledema, visual changes, headache, nausea, and/or vomiting)

Ocular

• Common (1% to 10%): Allergic conjunctivitis

Oncologic

• Frequency not reported (somatropin): New and recurrent malignancy (e.g., intracranial tumors, including meningiomas, as secondary neoplasms)

Other

• Very common (10% or more): Pyrexia (up to 16.5%)
• Common (1% to 10%): Otitis media, ear pain, arthropod bite
• Frequency not reported: Increased risk of mortality in patients with acute critical illness, sudden death in pediatric patients with Prader-Willi syndrome, elevated laboratory tests (e.g., phosphorus, alkaline phosphatase, parathyroid hormone)

Respiratory

• Very common (10% or more): Nasopharyngitis, including rhinitis, pharyngitis, rhinitis allergic, pharyngitis streptococcal, viral pharyngitis (33%)
• Common (1% to 10%): Cough, oropharyngeal pain, bronchitis

See also:

Further information

Ngenla side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer